Germ Cell Tumor of TestisSIGNALNCT07777887
Sentinel Node Identification Using Gamma and Near-Infrared Imaging in TesticulAr MaLignancies
An observational study of Germ Cell Tumor of Testis, run by N.N. Petrov National Medical Research Center of Oncology at 1 site in Russia.
Trial summary
Testicular seminoma is a malignant tumor with a very high probability of cure. Current treatment approaches provide excellent long-term cancer outcomes. However, some standard treatments, including radiotherapy and platinum-based chemotherapy, may cause side effects both during treatment and many years after its… Read more about this study
- Who is it for?
- Ages 18 to 60 years, men only
- Conditions the study is for
- Germ Cell Tumor of Testis
- What is being tested?
- Standard treatment: orchiectomy followed by drug therapy and, if necessary, retroperitoneal lymphadenectomy and sentinel lymph node mapping using technetium-99m (Tc-99m) and indocyanine green (ICG) with subsequent orchiectomy
- Type of treatment
- Surgery or procedure
- How many people
- 60 participants
- Where
- 1 siteRussia
- Study dates
- 1 Apr 2026to 1 Apr 2029
- How long will I take part?
- 1 Year
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 60 years
- Men only
- No healthy volunteers
- Adult
Study population: ## Study Population Description The study population will consist of adult male patients (≥18 years of age) with a primary testicular tumor suspicious for a testicular germ cell tumor (TGCT) who are candidates for radical inguinal orchiectomy (orchifuniculectomy). Eligible patients will have a primary testicular tumor with a maximum diameter of ≤5 cm, no evidence of distant metastatic disease (cM0), and limited or no radiologically detectable retroperitoneal lymph node involvement. The study will include patients with cN0 disease and eligible serum tumor marker levels, as well as selected patients with cN1-cN2 disease and limited retroperitoneal lymph node involvement, in accordance with the predefined eligibility criteria. Patients with distant metastatic disease, advanced retroperitoneal lymph node involvement, S2-S3 serum tumor marker levels, previous specific anticancer treatment for a testicular germ cell tumor, or contraindications.
Who may be able to join
- Presence of a primary testicular tumor suspicious for a testicular germ cell tumor (TGCT) and considered an indication for radical inguinal orchiectomy (orchifuniculectomy);
- Male gender;
- Maximum diameter of the primary testicular tumor (cT) ≤5 cm;
- One of the following clinical nodal and serum tumor marker criteria:
- - cN0 disease with serum tumor markers corresponding to S1 category: alpha-fetoprotein (AFP) 0-5.8 IU/mL and β-human chorionic gonadotropin (β-hCG) >2.5 and <1,000 IU/mL; or
- -cN1-cN2 disease, with no more than two radiologically suspicious retroperitoneal lymph nodes, and serum tumor markers corresponding to S0-S1 category;
Show all 9Show fewer
- No evidence of distant metastatic disease (cM0).
- Patient refusal to undergo adjuvant anticancer treatment (chemotherapy or radiotherapy) following radical inguinal orchiectomy, or unwillingness/inability to undergo close active surveillance.
- Ability to understand the study requirements and provision of written voluntary informed consent prior to participation in the study.
Who cannot join
- Maximum diameter of the primary testicular tumor (cT) >5 cm;
- Presence of distant metastatic disease (cM1);
- Serum tumor marker levels corresponding to S2-S3 category.
- Clinical stage cN1 with ≥2 retroperitoneal lymph nodes suspicious for metastatic involvement;
- Clinical stage cN3 disease;
- Any previous specific anticancer treatment for a testicular germ cell tumor, including systemic chemotherapy, radiotherapy, or prior retroperitoneal surgery for testicular cancer;
- Presence of any contraindication to minimally invasive surgery, administration of indocyanine green (ICG), or administration of the technetium-99m (Tc-99m)-labelled radiopharmaceutical used for sentinel lymph node mapping.
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Russia1 site, 1 recruiting
- Recruiting
FSBI "N.N. Petrov NMRC of oncology" MH of Russian Federation
Saint Petersburg, Sankt-Peterburg, 197758
Mariia Berkut, PhD, 89312870497, berkutv91@gmail.com
Pavel Gorlin, +79538151173, gorlin23@yandex.ru
About this study
Official title: Sentinel Node Identification Using Gamma Detection and Near-Infrared Fluorescence in Testicular Malignancies
Testicular seminoma is a malignant tumor with a very high probability of cure. Current treatment approaches provide excellent long-term cancer outcomes. However, some standard treatments, including radiotherapy and platinum-based chemotherapy, may cause side effects both during treatment and many years after its completion. In the long term, these treatments may be associated with an increased risk of cardiovascular disease, metabolic disorders, and secondary malignancies.
Because most patients with seminoma are successfully cured and have a long life expectancy, an important goal of modern cancer treatment is not only to achieve effective cancer control, but also to reduce the potential long-term adverse effects of treatment.
Read more
One possible treatment approach is minimally invasive retroperitoneal lymph node dissection (RPLND), performed using laparoscopic or robot-assisted surgery. This procedure allows the disease stage to be determined more accurately by establishing whether cancer cells are present in the retroperitoneal lymph nodes. In some patients, surgery may potentially provide effective disease control without the need for subsequent radiotherapy or chemotherapy.
However, currently available imaging methods, including computed tomography (CT), cannot always accurately determine whether individual retroperitoneal lymph nodes contain cancer cells. Studies have shown that in some patients undergoing RPLND for suspected lymph node involvement, no cancer cells are subsequently found in the removed lymph nodes. Therefore, there is a need to develop more accurate methods for identifying the lymph nodes that are most likely to be the first sites of cancer spread.
This study investigates a method for identifying sentinel lymph nodes. Sentinel lymph nodes are the lymph nodes that first receive lymphatic drainage from the area of the primary tumor and may therefore be the first lymph nodes to which cancer cells spread.
In this study, two complementary methods will be used to identify sentinel lymph nodes. The first involves the administration of a small amount of a radiopharmaceutical containing technetium-99m (Tc-99m), followed by single-photon emission computed tomography combined with computed tomography (SPECT/CT). During surgery, these lymph nodes will also be identified using a special gamma-detection device.
The second method involves the use of indocyanine green (ICG), a fluorescent dye that allows the surgeon to visualize lymphatic drainage pathways and lymph nodes during surgery using near-infrared fluorescence imaging.
The combination of these two methods may allow more accurate identification of sentinel lymph nodes and provide a better understanding of lymphatic drainage from testicular tumors.
Participants are being invited to participate because the characteristics of their disease meet the eligibility criteria for this study.
The main purpose of the study is to determine how accurately and reliably sentinel lymph nodes can be identified in patients with testicular seminoma using a combination of radionuclide and fluorescence-guided techniques.
The information obtained from this study may help to develop a more individualized approach to the surgical treatment of patients with seminoma. In the future, accurate identification of sentinel lymph nodes may make it possible to reduce the extent of surgery in selected patients, potentially decreasing surgical trauma and the risk of postoperative complications. At the same time, accurate detection of cancer involvement in lymph nodes may help identify patients who require additional anticancer treatment, such as systemic chemotherapy.
It is important to understand that the approach being evaluated is investigational, and its advantages over currently established approaches have not yet been conclusively demonstrated. Therefore, participation in this study cannot guarantee any additional direct medical benefit to participants. However, the information obtained from participants may contribute to improving the diagnosis and treatment of patients with testicular seminoma in the future.
Participation in this study is entirely voluntary. Before making decision, participants will have the opportunity to discuss the purpose of the study, the study procedures, possible benefits and risks, and alternative treatment options with their doctor. Their decision not to participate, or to withdraw from the study at a later time, will not affect their right to receive appropriate medical care.
- Conditions
- Germ Cell Tumor of Testis
- Being tested
- Standard treatment: orchiectomy followed by drug therapy and, if necessary, retroperitoneal lymphadenectomy, sentinel lymph node mapping using technetium-99m (Tc-99m) and indocyanine green (ICG) with subsequent orchiectomy
- Keywords
- germ cell tumor, seminoma, sentinel node, Gamma Detection, minimal invasive surgery
- Medical subject headings
- Testicular Germ Cell Tumor, Neoplasms, Germ Cell and Embryonal, Seminoma
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Standard treatment: orchiectomy followed by drug therapy and, if necessary, retroperitoneal lymphadenectomyProcedure or surgery
Participants assigned to the control group will receive standard-of-care treatment in accordance with current clinical guidelines and institutional practice. Patients will initially undergo radical inguinal orchiectomy with subsequent pathology examination. Following confirmation of the diagnosis and assessment of the pathological and clinical stage, each patient's case will be reviewed by a tumor board to determine the appropriate further treatment strategy (observation, chemotherapy or surgery).
Depending on the clinical stage, pathological findings, prognostic factors, and tumor board decision, participants will receive standard care. Following systemic treatment, patients will undergo clinical and radiological response assessment. RPLND may be performed when clinically indicated based on residual retroperitoneal disease based on CT scans.
sentinel lymph node mapping using technetium-99m (Tc-99m) and indocyanine green (ICG) with subsequent orchiectomyProcedure or surgery
Patients enrolled in the investigational group will undergo dual-tracer sentinel lymph node mapping and sentinel lymph node biopsy (SLNB) using a technetium-99m (Tc-99m)-labelled radiopharmaceutical and indocyanine green (ICG), followed by retroperitoneal lymph node dissection (RPLND) and radical inguinal orchiectomy.
Radiopharmaceutical Administration
Approximately 24 hours before surgery, patients will undergo administration of a Tc-99m-labelled colloidal radiopharmaceutical. Under ultrasound guidance using a high-frequency linear transducer, 0.2 mL of the radiopharmaceutical, with an activity of 740-860 MBq and a particle size of approximately 1,000 nm, will be injected beneath the tunica albuginea in the projection of the primary testicular tumor. The radiopharmaceutical will be prepared immediately before administration.
Preoperative SPECT/CT and Sentinel Lymph Node Mapping
Approximately 3 hours after radiopharmaceutical administration, radionuclide imaging of the lymphatic dr
| Study group | Role | What they receive |
|---|---|---|
| Standard-of-Care Group (Control Group) | Patients in the control group will undergo standard diagnostic and therapeutic management according to current clinical practice. Following radical inguinal orchiectomy and histopathological assessment, each patient's case will be reviewed by a multidisciplinary tumor board. Subsequent management, including active surveillance, systemic chemotherapy, radiotherapy, or other treatment when indicated, will be determined according to the pathological findings, clinical stage, and applicable clinical guidelines. Receives: Procedure: Standard treatment: orchiectomy followed by drug therapy and, if necessary, retroperitoneal lymphadenectomy | |
| SLNB Group (Investigational Group) | Participants in the investigational group will undergo sentinel lymph node mapping using technetium-99m (Tc-99m) and indocyanine green (ICG). Preoperative lymphatic mapping will be performed using SPECT/CT following administration of the Tc-99m-labelled radiopharmaceutical. During minimally invasive surgery, sentinel lymph nodes will be identified using gamma detection and near-infrared fluorescence imaging following ICG administration. Identified sentinel lymph nodes will be removed and subjected to histopathological and immunohistochemical examination. Retroperitoneal lymph node dissection will be performed according to the study protocol and the patient's clinical stage. Radical inguinal orchiectomy will subsequently be performed, and all surgical specimens will undergo histopathological examination. Receives: Procedure: sentinel lymph node mapping using technetium-99m (Tc-99m) and indocyanine green (ICG) with subsequent orchiectomy |
What is being measured
The primary outcome is the main question the study is designed to answer.
3-year relapse-free survival
Relapse-free survival is defined as the time from the date of completion of the initial surgical treatment to the first documented disease relapse or death from any cause, whichever occurs first.
Measured: 36 months
Secondary outcomes (2)
incidence of postoperative complications within 30 days after surgery
Postoperative complications will be recorded separately for the laparoscopic and robot-assisted surgical approaches. Complications will be classified according to the Clavien-Dindo classification, with major complications defined as Clavien-Dindo grade III or higher.
Measured: 30 days
treatment de-escalation rate
The treatment de-escalation rate will be defined as the proportion of patients in the investigational group who, following primary minimally invasive sentinel lymph node biopsy (SLNB) and subsequent histopathological assessment, have no indication for adjuvant systemic anticancer therapy.
The indication for adjuvant systemic therapy will be determined based on the final pathological findings, disease stage, and multidisciplinary tumor board assessment in accordance with the applicable clinical guidelines.
The treatment de-escalation rate will be calculated as the number of patients who do not require adjuvant systemic anticancer therapy following the SLNB-based surgical treatment strategy divided by the total number of evaluable patients undergoing the investigational procedure.
Measured: 52 weeks
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted20 Aug 2026
- Study start1 Apr 2026
- Primary completion1 Apr 2028 (estimated)
- Study completion1 Apr 2029 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Germ Cell Tumor of TestisStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case-control
- Time perspective
- Prospective
- Enrolment
- 60 participants (estimated)
- Target duration
- 1 Year
Sponsor and investigators
- Lead sponsor
- N.N. Petrov National Medical Research Center of Oncology
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07777887
- Sponsor's protocol ID
- SIGNAL
- Acronym
- SIGNAL
- Status last verified
- Aug 2026
- First submitted
- 17 Aug 2026
- Last updated
- 27 Aug 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided: De-identified individual participant data (IPD) may be shared upon reasonable request from qualified researchers, subject to approval by the study investigators and applicable institutional and ethical requirements. IPD will not be made publicly available due to patient confidentiality and data protection considerations. Any data sharing will be limited to information necessary to address the objectives of an approved research proposal.
Study at a glance
From the registry record, last updated by the sponsor on 27 Aug 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Sentinel Node Identification Using Gamma Detection and Near-Infrared Fluorescence in Testicular Malignancies
- ClinicalTrials.gov ID
- NCT07777887
- Acronym / sponsor ID
- SIGNAL / SIGNAL
- Conditions
- Germ Cell Tumor of Testis
- Keywords
- germ cell tumor, seminoma, sentinel node, Gamma Detection, minimal invasive surgery
- Study type
- Observational
- Recruitment status
- Recruiting
- Enrolment
- 60 participants (estimated)
- Lead sponsor
- N.N. Petrov National Medical Research Center of OncologyUniversity, hospital or other
- Study start
- 1 Apr 2026 (actual)
- Primary completion
- 1 Apr 2028 (estimated)
- Study completion
- 1 Apr 2029 (estimated)
- First posted
- 20 Aug 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Testicular seminoma is a malignant tumor with a very high probability of cure. Current treatment approaches provide excellent long-term cancer outcomes. However, some standard treatments, including radiotherapy and platinum-based chemotherapy, may cause side effects both during treatment and many years after its completion. In the long term, these treatments may be associated with an increased risk of cardiovascular disease, metabolic disorders, and secondary malignancies.
Because most patients with seminoma are successfully cured and have a long life expectancy, an important goal of modern cancer treatment is not only to achieve effective cancer control, but also to reduce the potential long-term adverse effects of treatment.
One possible treatment approach is minimally invasive retroperitoneal lymph node dissection (RPLND), performed using laparoscopic or robot-assisted surgery. This procedure allows the disease stage to be determined more accurately by establishing whether cancer cells are present in the retroperitoneal lymph nodes. In some patients, surgery may potentially provide effective disease control without the need for subsequent radiotherapy or chemotherapy.
However, currently available imaging methods, including computed tomography (CT), cannot always accurately determine whether individual retroperitoneal lymph nodes contain cancer cells. Studies have shown that in some patients undergoing RPLND for suspected lymph node involvement, no cancer cells are subsequently found in the removed lymph nodes. Therefore, there is a need to develop more accurate methods for identifying the lymph nodes that are most likely to be the first sites of cancer spread.
This study investigates a method for identifying sentinel lymph nodes. Sentinel lymph nodes are the lymph nodes that first receive lymphatic drainage from the area of the primary tumor and may therefore be the first lymph nodes to which cancer cells spread.
In this study, two complementary methods will be used to identify sentinel lymph nodes. The first involves the administration of a small amount of a radiopharmaceutical containing technetium-99m (Tc-99m), followed by single-photon emission computed tomography combined with computed tomography (SPECT/CT). During surgery, these lymph nodes will also be identified using a special gamma-detection device.
The second method involves the use of indocyanine green (ICG), a fluorescent dye that allows the surgeon to visualize lymphatic drainage pathways and lymph nodes during surgery using near-infrared fluorescence imaging.
The combination of these two methods may allow more accurate identification of sentinel lymph nodes and provide a better understanding of lymphatic drainage from testicular tumors.
Participants are being invited to participate because the characteristics of their disease meet the eligibility criteria for this study.
The main purpose of the study is to determine how accurately and reliably sentinel lymph nodes can be identified in patients with testicular seminoma using a combination of radionuclide and fluorescence-guided techniques.
The information obtained from this study may help to develop a more individualized approach to the surgical treatment of patients with seminoma. In the future, accurate identification of sentinel lymph nodes may make it possible to reduce the extent of surgery in selected patients, potentially decreasing surgical trauma and the risk of postoperative complications. At the same time, accurate detection of cancer involvement in lymph nodes may help identify patients who require additional anticancer treatment, such as systemic chemotherapy.
It is important to understand that the approach being evaluated is investigational, and its advantages over currently established approaches have not yet been conclusively demonstrated. Therefore, participation in this study cannot guarantee any additional direct medical benefit to participants. However, the information obtained from participants may contribute to improving the diagnosis and treatment of patients with testicular seminoma in the future.
Participation in this study is entirely voluntary. Before making decision, participants will have the opportunity to discuss the purpose of the study, the study procedures, possible benefits and risks, and alternative treatment options with their doctor. Their decision not to participate, or to withdraw from the study at a later time, will not affect their right to receive appropriate medical care.
Study design
- Observational model
- Case-control
- Time perspective
- Prospective
- Target follow-up
- 1 Year
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Standard-of-Care Group (Control Group) | – | Procedure: Standard treatment: orchiectomy followed by drug therapy and, if necessary, retroperitoneal lymphadenectomyPatients in the control group will undergo standard diagnostic and therapeutic management according to current clinical practice. Following radical inguinal orchiectomy and histopathological assessment, each patient's case will be reviewed by a multidisciplinary tumor board. Subsequent management, including active surveillance, systemic chemotherapy, radiotherapy, or other treatment when indicated, will be determined according to the pathological findings, clinical stage, and applicable clinical guidelines. |
| SLNB Group (Investigational Group) | – | Procedure: sentinel lymph node mapping using technetium-99m (Tc-99m) and indocyanine green (ICG) with subsequent orchiectomyParticipants in the investigational group will undergo sentinel lymph node mapping using technetium-99m (Tc-99m) and indocyanine green (ICG). Preoperative lymphatic mapping will be performed using SPECT/CT following administration of the Tc-99m-labelled radiopharmaceutical. During minimally invasive surgery, sentinel lymph nodes will be identified using gamma detection and near-infrared fluorescence imaging following ICG administration. Identified sentinel lymph nodes will be removed and subjected to histopathological and immunohistochemical examination. Retroperitoneal lymph node dissection will be performed according to the study protocol and the patient's clinical stage. Radical inguinal orchiectomy will subsequently be performed, and all surgical specimens will undergo histopathological examination. |
Who may qualify
- Ages
- 18 to 60 years
- Sex
- Male only
- Healthy volunteers
- Not accepted
- Age groups
- Adult
- Study population
- ## Study Population Description The study population will consist of adult male patients (≥18 years of age) with a primary testicular tumor suspicious for a testicular germ cell tumor (TGCT) who are candidates for radical inguinal orchiectomy (orchifuniculectomy). Eligible patients will have a primary testicular tumor with a maximum diameter of ≤5 cm, no evidence of distant metastatic disease (cM0), and limited or no radiologically detectable retroperitoneal lymph node involvement. The study will include patients with cN0 disease and eligible serum tumor marker levels, as well as selected patients with cN1-cN2 disease and limited retroperitoneal lymph node involvement, in accordance with the predefined eligibility criteria. Patients with distant metastatic disease, advanced retroperitoneal lymph node involvement, S2-S3 serum tumor marker levels, previous specific anticancer treatment for a testicular germ cell tumor, or contraindications.
Key inclusion criteria (9 listed)
- Presence of a primary testicular tumor suspicious for a testicular germ cell tumor (TGCT) and considered an indication for radical inguinal orchiectomy (orchifuniculectomy);
- Male gender;
- Maximum diameter of the primary testicular tumor (cT) ≤5 cm;
- One of the following clinical nodal and serum tumor marker criteria:
- - cN0 disease with serum tumor markers corresponding to S1 category: alpha-fetoprotein (AFP) 0-5.8 IU/mL and β-human chorionic gonadotropin (β-hCG) >2.5 and <1,000 IU/mL; or
Key exclusion criteria (7 listed)
- Maximum diameter of the primary testicular tumor (cT) >5 cm;
- Presence of distant metastatic disease (cM1);
- Serum tumor marker levels corresponding to S2-S3 category.
- Clinical stage cN1 with ≥2 retroperitoneal lymph nodes suspicious for metastatic involvement;
- Clinical stage cN3 disease;
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Standard treatment: orchiectomy followed by drug therapy and, if necessary, retroperitoneal lymphadenectomyParticipants assigned to the control group will receive standard-of-care treatment in accordance with current clinical guidelines and institutional practice. Patients will initially undergo radical inguinal orchiectomy with subsequent pathology examination. Following confirmation of the diagnosis and assessment of the pathological and clinical stage, each patient's case will be reviewed by a tumor board to determine the appropriate further treatment strategy (observation, chemotherapy or surgery). Depending on the clinical stage, pathological findings, prognostic factors, and tumor board decision, participants will receive standard care. Following systemic treatment, patients will undergo clinical and radiological response assessment. RPLND may be performed when clinically indicated based on residual retroperitoneal disease based on CT scans. | Procedure or surgery | Standard-of-Care Group (Control Group) |
| sentinel lymph node mapping using technetium-99m (Tc-99m) and indocyanine green (ICG) with subsequent orchiectomyPatients enrolled in the investigational group will undergo dual-tracer sentinel lymph node mapping and sentinel lymph node biopsy (SLNB) using a technetium-99m (Tc-99m)-labelled radiopharmaceutical and indocyanine green (ICG), followed by retroperitoneal lymph node dissection (RPLND) and radical inguinal orchiectomy. Radiopharmaceutical Administration Approximately 24 hours before surgery, patients will undergo administration of a Tc-99m-labelled colloidal radiopharmaceutical. Under ultrasound guidance using a high-frequency linear transducer, 0.2 mL of the radiopharmaceutical, with an activity of 740-860 MBq and a particle size of approximately 1,000 nm, will be injected beneath the tunica albuginea in the projection of the primary testicular tumor. The radiopharmaceutical will be prepared immediately before administration. Preoperative SPECT/CT and Sentinel Lymph Node Mapping Approximately 3 hours after radiopharmaceutical administration, radionuclide imaging of the lymphatic dr | Procedure or surgery | SLNB Group (Investigational Group) |
Primary outcome
3-year relapse-free survival
Time frame: 36 months
Relapse-free survival is defined as the time from the date of completion of the initial surgical treatment to the first documented disease relapse or death from any cause, whichever occurs first.
2 secondary outcomes
incidence of postoperative complications within 30 days after surgery
Time frame: 30 days
treatment de-escalation rate
Time frame: 52 weeks
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 27 Aug 2026.
- Individual participant dataSharing planned: Undecided. De-identified individual participant data (IPD) may be shared upon reasonable request from qualified researchers, subject to approval by the study investigators and applicable institutional and ethical requirements. IPD will not be made publicly available due to patient confidentiality and data protection considerations. Any data sharing will be limited to information necessary to address the objectives of an approved research proposal.
Related trials for Germ Cell Tumor of Testis
Recruiting
Effect of Hypnosis in the Management of Anxiety and Chemo-induced Symptoms in Adolescents and Young Adults With Sarcoma or Germ Cell Tumor and in Young Women With Breast Cancer
Sarcoma, Germ Cell Tumor of Testis
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Germ Cell Tumor of Testis, run by N.N. Petrov National Medical Research Center of Oncology at 1 site in Russia.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 9 inclusion and 7 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 27 Aug 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Russia. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Mariya Berkut, PhD (+ 7 9312870497, berkutv91@gmail.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
3-year relapse-free survival (time frame: 36 months). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 27 Aug 2026; AzTrials last refreshed its copy on 30 Oct 2026.